ImmunityBio Inc [NASDAQ: IBRX] price plunged by -5.90 percent to reach at -$0.19.
The one-year IBRX stock forecast points to a potential upside of 75.14. The average equity rating for IBRX stock is currently 1.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on ImmunityBio Inc [IBRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBRX shares is $12.19 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBRX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for ImmunityBio Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 10, 2025. While these analysts kept the previous recommendation, Piper Sandler raised their target price from $10 to $4. The new note on the price target was released on May 12, 2023, representing the official price target for ImmunityBio Inc stock. Previously, the target price had yet another raise to $8, while Jefferies analysts kept a Buy rating on IBRX stock.
The Average True Range (ATR) for ImmunityBio Inc is set at 0.33, with the Price to Sales ratio for IBRX stock in the period of the last 12 months amounting to 301.83.
IBRX Stock Performance Analysis:
ImmunityBio Inc [IBRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.55. With this latest performance, IBRX shares dropped by -4.42% in over the last four-week period, additionally sinking by -27.16% over the last 6 months – not to mention a drop of -42.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBRX stock in for the last two-week period is set at 44.48, with the RSI for the last a single of trading hit 40.77, and the three-weeks RSI is set at 45.75 for ImmunityBio Inc [IBRX]. The present Moving Average for the last 50 days of trading for this stock 3.01, while it was recorded at 3.44 for the last single week of trading, and 4.60 for the last 200 days.
Insight into ImmunityBio Inc Fundamentals:
ImmunityBio Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.64 and a Current Ratio set at 2.68.
IBRX Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IBRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ImmunityBio Inc go to 32.58%.
ImmunityBio Inc [IBRX] Institutonal Ownership Details
The top three institutional holders of IBRX stocks are: VANGUARD GROUP INC with ownership of 13.83 million shares, which is approximately 2.0558%. BLACKROCK INC., holding 11.42 million shares of the stock with an approximate value of $$72.19 million in IBRX stocks shares; and BLACKROCK INC., currently with $$49.7 million in IBRX stock with ownership which is approximately 1.1688%.
